State of the Heart 2020
Details & Video
Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)
The program was developed by the Canadian Collaborative Research Network and was presented as three live virtual events in July/August 2020. We are pleased to make the recordings of these live sessions available to you through MD-Online. Please select the sessions below to participate. The PROGRAM AGENDA is available here. The PROGRAM SLIDES are available from the CCRN booth in the virtual exhibit hall link below.
Thank you to our OnDemand sponsors who made it possible for us to share the recordings of this program.
CLICK TO VISIT THE VIRTUAL EXHIBIT HALL
The following sponsors provided support to CCRN for the OnDemand recording through an unrestricted educational grant:
Overview & Objectives
The State of the Heart program was developed by the Canadian Collaborative Research Network and has been specifically designed for general practitioners, specialists, nurse practitioners, nurses, pharmacists, technicians and other allied health professionals who have an interest in cardiovascular disease. This program covers the latest topics in cardiovascular and metabolic disease, guidelines, late-breaking clinical trial results, and addresses patient care issues encountered in daily practice. For this program, CCRN hosts an outstanding faculty of Canadian and international leaders that provide excellent teaching and offer opportunity for group discussion surrounding real-world implications of the current evidence.
Planning Committee
Planning Committee
Agenda
Agenda
| Program Chapter | Duration (Min:Sec) | Presenter |
|---|---|---|
| Session 1 - Beyond statins: PCKS9 inhibitors following acute coronary syndromes – ODYSSEY Outcomes and EVOPACS | Rob Hegele | |
| Session 1 - Beyond statins: Icosapent ethyl and the REDUCE-IT study | Milan Gupta | |
| Session 1 - Does the PARAGON HF study provide a new option for treatment in HFpEF? | Shelley Zieroth | |
| Session 1 - Is there an interaction between ACEi/ARB and COVID-19? | Nadia Khan | |
| Session 2 - Antithrombotic combinations for AF with concomitant ACS/ PCI– clearing the confusion | Alan Bell | |
| Session 2 - Cardiorenal protection in diabetes: Should SGLT2 inhibitors and GLP1 agonists be first-line therapy? | Hertzel Gerstein | |
| Session 2 - Is dapagliflozin the new darling in heart failure management? | Nadia Giannetti | |
| Session 2 - LDL control with twice-yearly injections – will ORION deliver? | Rob Hegele | |
| Session 3 - Is colchicine a cardiovascular drug? Insights from the COLCOT study | Jean-Claude Tardif | |
| Session 3 - Is revascularization warranted for stable ASCVD? The ISCHEMIA study | G.B. John Mancini | |
| Session 3 - Peripheral arterial disease – underdiagnosed and undertreated | Milan Gupta | |
| Session 3 - Cardiovascular safety of cannabis | Paul Oh |
| Program Chapter | Duration (Min:Sec) & Presenter |
|---|---|
| Session 1 - Beyond statins: PCKS9 inhibitors following acute coronary syndromes – ODYSSEY Outcomes and EVOPACS | Rob Hegele |
| Session 1 - Beyond statins: Icosapent ethyl and the REDUCE-IT study | Milan Gupta |
| Session 1 - Does the PARAGON HF study provide a new option for treatment in HFpEF? | Shelley Zieroth |
| Session 1 - Is there an interaction between ACEi/ARB and COVID-19? | Nadia Khan |
| Session 2 - Antithrombotic combinations for AF with concomitant ACS/ PCI– clearing the confusion | Alan Bell |
| Session 2 - Cardiorenal protection in diabetes: Should SGLT2 inhibitors and GLP1 agonists be first-line therapy? | Hertzel Gerstein |
| Session 2 - Is dapagliflozin the new darling in heart failure management? | Nadia Giannetti |
| Session 2 - LDL control with twice-yearly injections – will ORION deliver? | Rob Hegele |
| Session 3 - Is colchicine a cardiovascular drug? Insights from the COLCOT study | Jean-Claude Tardif |
| Session 3 - Is revascularization warranted for stable ASCVD? The ISCHEMIA study | G.B. John Mancini |
| Session 3 - Peripheral arterial disease – underdiagnosed and undertreated | Milan Gupta |
| Session 3 - Cardiovascular safety of cannabis | Paul Oh |
Sponsorship
This program was developed by the Canadian Collaborative Research Network and made possible through an educational grant from : BMS/Pfizer Alliance, HLS Therapeutics, Boehringer Ingelheim, Novartis, Sanofi, Amgen
The OnDemand presentations were made possible with additional support from: